Essex Woodlands raises $360M for new life sciences fund

Essex Woodlands is making progress with its ninth life sciences fund. The group noted in an SEC filing that it has raised $360 million of a planned $750 million fund, up from the $221 million it had raised and then reported last year. But there's still a long way to go for Essex Woodlands as it follows up on Fund VIII, which closed 6 years ago with $900 million. The global group--with offices in London, Palo Alto, Houston, New York and Shanghai--invests in drugs, devices and service companies. More

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.